newsfilter
← Latest News
GlobeNewswire·

Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders

CMNDSPRC
  • Clearmind Medicine Inc. announced the USPTO publication of a U.S. patent application for its combination therapy of 5-methoxy-2-aminoindane (MEAI) & N-Acylethanolamines like Palmitoylethanolamide (PEA).
  • The patent application stems from Clearmind's collaboration with SciSparc Ltd. to address binge behavior disorders including excessive alcohol consumption, binge eating, smoking, compulsive shopping, & problematic sexual conduct.
  • The therapy leverages MEAI's neuroplastic properties to reduce impulsivity & reward-seeking behavior, potentially offering a safer & more effective treatment for substance use disorders & addictions than current options.
  • Clearmind has filed 13 patents related to this collaboration targeting alcohol use disorder, cocaine addiction, obesity, weight loss, & depression, with preclinical data supporting MEAI's efficacy in mitigating addictive behaviors while preserving natural reward pathways.
  • CEO Dr. Adi Zuloff-Shani stated the publication advances the company's mission to pioneer next-generation treatments for binge behaviors & strengthens its position as a leader in psychedelic therapeutics.
  • The company's intellectual portfolio currently consists of 19 patent families including 31 granted patents, with plans to seek additional patents & acquire new intellectual property opportunistically.
  • Clearmind Medicine Inc. shares trade on Nasdaq under the symbol "CMND" & the Frankfurt Stock Exchange under the symbol "CWY0".